Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




AI Tool Analyzes 30K Data Points Per Medical Imaging Pixel in Cancer Search

By LabMedica International staff writers
Posted on 16 Jan 2025

A new artificial intelligence (AI)-powered tool can detect cell-level characteristics of cancer by analyzing data from very small tissue samples, some as tiny as 400 square micrometers, equivalent to the width of five human hairs. More...

The tool, called MISO (Multi-modal Spatial Omics), processes vast amounts of data and applies insights to even the smallest regions on medical images. It has the potential to guide doctors toward the most effective therapies for various cancers, according to a recent paper about MISO published in Nature Methods.

MISO was developed by researchers at the Perelman School of Medicine at the University of Pennsylvania (Philadelphia, PA, USA) to work in the field of "spatial multi-omics." This area of research aims to gain insights into different conditions by considering the physical arrangement of tissue while examining various "-omics" modalities, such as transcriptomics (gene expression), proteomics (proteins), and metabolomics (metabolites and their processes), among others. In spatial transcriptomics, for example, a single pixel in an image contains 20,000 to 30,000 data points that need to be analyzed across multiple -omics layers, and this number can increase significantly if multiple omic layers are considered. By comparison, MRI and CT scans have only one data point (shades of gray) per pixel to interpret. Without AI tools like MISO, doctors and researchers would find it nearly impossible to uncover the valuable insights that the system can detect.

Using MISO, the researchers uncovered new information about several types of cancer, including bladder, gastric, and colorectal cancers, by analyzing data and images from donated patient tissue. In bladder cancer, MISO identified a specific group of cells responsible for forming tertiary lymphoid structures, which are associated with better responses to immunotherapy. In gastric cancer, MISO was able to differentiate cancer cells from the surrounding mucosa. In colorectal cancer, the system identified various sub-classes of cancer cells, shedding light on the distinct malignant cells within a single tumor. MISO was also used to analyze non-cancerous brain tissue structures.

These breakthroughs can guide more effective therapies, improve survival rates, and provide insights that are very challenging, if not impossible, to obtain without an advanced AI tool like MISO. Moving forward, the team aims to expand their knowledge of spatial -omics and pathology imaging to enhance MISO’s capabilities, including the ability to analyze multiple tissue samples simultaneously, which would greatly increase its output. While some data, such as epigenetic marks (chemicals that regulate DNA and are influenced by the environment), have not yet been widely measured, MISO’s AI system allows it to "learn" from the information it processes, enabling it to recognize new data as it becomes more available.

“As the field of spatial omics advances, it has become possible to measure multiple -omics modalities from the same tissue slice, providing complementary information and offering a more comprehensive, insightful view,” said Mingyao Li, PhD, the study’s senior author and a professor of Biostatistics and Digital Pathology. “MISO addresses a huge data challenge by enabling simultaneous analysis of all spatial -omics modalities, as well as microscopic anatomy images when available. It is the only method that is able to handle datasets like these with hundreds of thousands of cells per sample.”

Related Links:
Perelman School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.